Search

Bruce A Gomes

from Pleasanton, CA
Age ~73
Get Report
Also known as:
Bruce Te Gomes, Bruce A Gomez, Ashley Gomes, Virginia Gomes
Phone and address:
47 Bunker Ln, Pleasanton, CA 94566
(925) 484-4916
Related to:
Barrett S Gomes, 45Erwin J Gomes, 97Kipp F Peppel, 50Virginia D Gomes, 73Diane E Gomes, 68Courtney D Gomes, 46Molly E Gomes, 35Jessica A Bremer, 47C GomesAndrew M Olson, 48Amanda K Gomes, 37Jeffery R Kettmann, 42
Connected to:
Aaron Gomes, 51Aijalon M Gomes, 45Alberto A Gomes, 56Alcione Gomes, 59Alfred J Gomes, 78Alize Gomes, 29Almir P Gomes, 52Amarildo Gomes, 45Ana Gomes, 46Antoinette Gomes, 55

Bruce Gomes Phones & Addresses

  • 47 Bunker Ln, Pleasanton, CA 94566 (925) 484-4916
  • Dublin, CA
  • Fremont, CA
  • Incline Village, NV
  • Brentwood, CA
  • Newark, CA

Resumes

Resumes

Bruce Gomes Photo 1

Bruce Gomes

View page
Location:
United States
Bruce Gomes Photo 2

Independent Management Consulting Professional

View page
Location:
San Francisco Bay Area
Industry:
Management Consulting

Business Records

Name / Title
Company / Classification
Phones & Addresses
Bruce Gomes
President
Vintage at Incline Homeowners' Association
948 Tahoe Blvd, Incline Village, NV 89451
900 Southwood Blvd, Incline Village, NV 89451
Bruce Gomes
President, Owner
NILES MACHINE & TOOL WORKS, INC
The Company Is A Precision Machine Shop · Machine Shops
225 Mtn Vis Pkwy, Livermore, CA 94550
225 Mt Vis Pkwy, Livermore, CA 94550
(925) 273-1100, (925) 960-1878, (925) 273-1111

Publications

Us Patents

Isolated Antibody Which Specifically Binds To Pcsk9

View page
US Patent:
8080243, Dec 20, 2011
Filed:
Sep 11, 2009
Appl. No.:
12/558312
Inventors:
Hong Liang - San Francisco CA, US
Yasmina Noubia Abdiche - Mountain View CA, US
Javier Fernando Chaparro Riggers - San Mateo CA, US
Bruce Charles Gomes - Ashburnham MA, US
Julie Jia Li Hawkins - Old Lyme CT, US
Jaume Pons - San Bruno CA, US
Yuli Wang - San Diego CA, US
Assignee:
Rinat Neuroscience Corp. - South San Francisco CA
Pfizer Inc. - New York NY
International Classification:
A61K 39/395
US Classification:
4241301, 4241331
Abstract:
The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

Isolated Nucleic Acid Encoding An Antibody Which Specifically Binds To Pcsk9 And A Host Cell That Produces The Antibody

View page
US Patent:
8399646, Mar 19, 2013
Filed:
Sep 2, 2011
Appl. No.:
13/225119
Inventors:
Hong Liang - San Francisco CA, US
Yasmina Noubia Abdiche - Mountain View CA, US
Javier Fernando Chaparro Riggers - San Mateo CA, US
Bruce Charles Gomes - Ashburnham MA, US
Julie Jia Li Hawkins - Old Lyme CT, US
Jaume Pons - San Bruno CA, US
Yuli Wang - San Diego CA, US
Assignee:
Rinat Neuroscience Corp. - South San Francisco CA
Pfizer Inc. - New York NY
International Classification:
C07H 21/04
C12P 21/08
C12N 5/07
US Classification:
536 2353, 435 691, 435326, 435329
Abstract:
The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

Method For Reducing A Level Of Ldl-Cholesterol By An Antibody That Specifically Binds To Pcsk9

View page
US Patent:
8426363, Apr 23, 2013
Filed:
Sep 2, 2011
Appl. No.:
13/225265
Inventors:
Hong Liang - San Francisco CA, US
Yasmina Noubia Abdiche - Mountain View CA, US
Javier Fernando Chaparro Riggers - San Mateo CA, US
Bruce Charles Gomes - Ashburnham MA, US
Julie Jia Li Hawkins - Old Lyme CT, US
Jaume Pons - San Bruno CA, US
Yuli Wang - San Diego CA, US
Assignee:
Rinat Neuroscience Corp. - South San Francisco CA
Pfizer Inc. - New York NY
International Classification:
A61P 3/06
A61K 38/00
US Classification:
514 74, 4241301, 4241311
Abstract:
The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

Antibodies With Ph Dependent Antigen Binding

View page
US Patent:
20110229489, Sep 22, 2011
Filed:
Mar 10, 2011
Appl. No.:
13/045345
Inventors:
Jaume Pons - San Bruno CA, US
Jeffrey Raymond Chabot - Medford MA, US
Javier Fernando Chaparro Riggers - San Mateo CA, US
Bruce Charles Gomes - Ashburnham MA, US
Hong Liang - San Francisco CA, US
Kapil Mayawala - Peabody MA, US
Arvind Rajpal - San Francisco CA, US
David Louis Shelton - Oakland CA, US
International Classification:
A61K 39/395
C07K 16/00
C07K 16/40
C07K 16/42
C07K 16/18
C07H 21/04
A61P 3/06
C40B 40/10
C12N 5/10
C12N 1/00
US Classification:
4241581, 5303871, 5303917, 5303891, 5303872, 5303892, 4241301, 5303873, 536 2353, 506 18, 435325, 435243
Abstract:
The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the Kor kratio at pH 5.5/pH 7.4 or at pH 6.0/pH 7.4 is more than, or ranges between, 2, 3, 4, 8, 10, 16, 20, 30, 40, or 100 or more. Such pH dependent antibodies preferentially dissociate from the antigen in the endosome. This can increase antibody half life, as compared to antibodies with equivalent Ks at pH 7.4 but with no pH dependent binding, when the antigen is one that undergoes antigen-mediated clearance (e.g., PCSK9). Antibodies with pH dependent binding can decrease total antigen half life when the antigen undergoes reduced clearance when bound to antibody (e.g., IL6). Antibodies with pH dependent binding can also prolong the decrease in antigen which is not antibody-bound. This can be important when antagonizing a target antigen typically present at high levels (e.g., IgE, DKK1, C5 and SOST). In addition, such antibodies can increase antigen half life when the antigen is a receptor and the receptor has increased clearance when bound to antibody (e.g, GMCSF receptor).

Pcsk9 Antagonists

View page
US Patent:
20130273069, Oct 17, 2013
Filed:
Apr 4, 2013
Appl. No.:
13/857063
Inventors:
Javier Fernando CHAPARRO RIGGERS - San Mateo CA, US
Bruce Charles GOMES - Ashburnham MA, US
Julie Jia Li HAWKINS - Weston CT, US
Jaume PONS - San Francisco CA, US
Xiayang QIU - Mystic CT, US
Pavel STROP - San Mateo CA, US
Yuli WANG - San Diego CA, US
International Classification:
C07K 16/40
A61K 45/06
A61K 39/395
US Classification:
4241581, 5303891, 5303879, 5303873
Abstract:
The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

Antibodies With Ph Dependent Antigen Binding

View page
US Patent:
20200024366, Jan 23, 2020
Filed:
Mar 8, 2019
Appl. No.:
16/296852
Inventors:
- New York NY, US
- South San Francisco CA, US
Javier Fernando CHAPARRO RIGGERS - San Mateo CA, US
Bruce Charles GOMES - Ashburnham MA, US
Hong LIANG - Hillsborough CA, US
KapiI MAYAWALA - New Brunswick NJ, US
Arvind RAJPAL - San Francisco CA, US
David Louis SHELTON - Oakland CA, US
International Classification:
C07K 16/42
C07K 16/40
C07K 16/28
Abstract:
The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the Kor kratio at pH 5.5/pH 7.4 or at pH 6.0/pH 7.4 is more than, or ranges between, 2, 3, 4, 8, 10, 16, 20, 30, 40, or 100 or more. Such pH dependent antibodies preferentially dissociate from the antigen in the endosome. This can increase antibody half life, as compared to antibodies with equivalent Ks at pH 7.4 but with no pH dependent binding, when the antigen is one that undergoes antigen-mediated clearance (e.g., PCSK9). Antibodies with pH dependent binding can decrease total antigen half life when the antigen undergoes reduced clearance when bound to antibody (e.g., IL6). Antibodies with pH dependent binding can also prolong the decrease in antigen which is not antibody-bound. This can be important when antagonizing a target antigen typically present at high levels (e.g., IgE, DKK1, C5 and SOST). In addition, such antibodies can increase antigen half life when the antigen is a receptor and the receptor has increased clearance when bound to antibody (e.g., GMCSF receptor).

Pc33718E

View page
US Patent:
20160096898, Apr 7, 2016
Filed:
Sep 24, 2015
Appl. No.:
14/864750
Inventors:
- South San Francisco CA, US
- New York NY, US
Javier Fernando CHAPARRO RIGGERS - San Mateo CA, US
Bruce Charles GOMES - Ashburnham MA, US
Julie Jia Li HAWKINS - Weston CT, US
Jaume PONS - San Francisco CA, US
Xiayang QIU - Mystic CT, US
Pavel STROP - San Mateo CA, US
Yuli WANG - San Diego CA, US
Assignee:
PFIZER INC. - New York NY
RINAT NEUROSCIENCE CORP. - South San Francisco CA
International Classification:
C07K 16/40
Abstract:
The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

Antibodies With Ph Dependent Antigen Binding

View page
US Patent:
20150266974, Sep 24, 2015
Filed:
Apr 3, 2015
Appl. No.:
14/677983
Inventors:
- South San Francisco CA, US
- New York NY, US
Javier Fernando CHAPARRO RIGGERS - San Mateo CA, US
Bruce Charles GOMES - Ashburnham MA, US
Hong LIANG - San Francisco CA, US
Kapil MAYAWALA - Peabody MA, US
Arvind RAJPAL - San Francisco CA, US
David Louis SHELTON - Oakland CA, US
International Classification:
C07K 16/42
C07K 16/40
C07K 16/28
Abstract:
The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the Kor kratio at pH 5.5/pH 7.4 or at pH 6.0/pH 7.4 is more than, or ranges between, 2, 3, 4, 8, 10, 16, 20, 30, 40, or 100 or more. Such pH dependent antibodies preferentially dissociate from the antigen in the endosome. This can increase antibody half life, as compared to antibodies with equivalent Ks at pH 7.4 but with no pH dependent binding, when the antigen is one that undergoes antigen-mediated clearance (e.g., PCSK9). Antibodies with pH dependent binding can decrease total antigen half life when the antigen undergoes reduced clearance when bound to antibody (e.g., IL6). Antibodies with pH dependent binding can also prolong the decrease in antigen which is not antibody-bound. This can be important when antagonizing a target antigen typically present at high levels (e.g., IgE, DKK1, C5 and SOST). In addition, such antibodies can increase antigen half life when the antigen is a receptor and the receptor has increased clearance when bound to antibody (e.g, GMCSF receptor).
Control profile
Bruce A Gomes from Pleasanton, CA, age ~73 Get Report